ABFM and KSA Asthma Certification Exam - 2026 Practice Questions
1. What is the gold standard for confirming the diagnosis of asthma in patients
over the age of 5?
A. Peak Expiratory Flow (PEF) monitoring for one week
B. Chest X-ray showing hyperinflation
C. Spirometry showing reversible airflow obstruction
D. Measurement of Fractional Exhaled Nitric Oxide (FeNO)
Answer: C
Rationale: Spirometry is the gold standard for diagnosing asthma by demonstrating
airflow obstruction that is reversible after administration of a bronchodilator.
2. According to GINA guidelines, what is the criteria for significant
bronchodilator reversibility in adults?
A. Increase in FEV1 of >10% and >100 mL
B. Increase in FEV1 of >15% and >300 mL
C. Increase in FEV1 of >20% and >400 mL
D. Increase in FEV1 of >12% and >200 mL
Answer: D
Rationale: A significant bronchodilator response is defined as an increase in FEV1 of more
than 12% and more than 200 mL from the baseline.
,3. A patient has asthma symptoms 3 days a week and wakes up 3 times a month
due to asthma. How is this severity classified?
A. Mild Persistent
B. Intermittent
C. Moderate Persistent
D. Severe Persistent
Answer: A
Rationale: Mild persistent asthma is characterized by symptoms occurring more than 2
days per week (but not daily) and nighttime awakenings 3-4 times per month.
4. Under the GINA 2024 Track 1 recommendation, what is the preferred reliever
for all steps?
A. Short-Acting Beta-Agonist (SABA) alone
B. Oral Corticosteroids
C. Low-dose ICS + Salmeterol
D. Low-dose Inhaled Corticosteroid (ICS) + Formoterol
Answer: D
Rationale: GINA Track 1 recommends low-dose ICS-formoterol as the preferred reliever to
reduce the risk of severe exacerbations compared to using a SABA alone.
5. Which medication is known to have a Black Box Warning for serious
neuropsychiatric events, such as agitation and suicidal thoughts?
A. Montelukast
B. Albuterol
C. Fluticasone
D. Theophylline
Answer: A
Rationale: Montelukast (Singulair) carries a FDA Black Box Warning due to the risk of
serious neuropsychiatric events.
, 6. What is the primary mechanism of action of Omalizumab in treating severe
allergic asthma?
A. IL-5 Inhibition
B. IL-4 Receptor Antagonism
C. Binding to circulating IgE
D. Inhibiting Leukotriene synthesis
Answer: C
Rationale: Omalizumab is a monoclonal antibody that binds to circulating IgE, preventing
it from binding to mast cells and basophils.
7. Which of the following is the most appropriate next step for a patient on
medium-dose ICS-LABA whose asthma remains uncontrolled?
A. Add a Long-Acting Muscarinic Antagonist (LAMA)
B. Switch to SABA only
C. Discontinue ICS and start Montelukast
D. Decrease the ICS dose to minimize side effects
Answer: A
Rationale: For patients uncontrolled on Step 4 (medium-dose ICS-LABA), adding a LAMA
(like Tiotropium) is a recommended option.
8. A 28-year-old pregnant woman has well-controlled asthma on Budesonide.
What is the recommendation regarding her treatment?
A. Stop all medications to protect the fetus
B. Switch to a SABA only
C. Switch to oral prednisone
D. Continue the current ICS as the benefits of control outweigh risks
Answer: D
Rationale: Maintaining asthma control is vital during pregnancy; Budesonide is the
preferred ICS due to extensive safety data, and treatment should continue.
1. What is the gold standard for confirming the diagnosis of asthma in patients
over the age of 5?
A. Peak Expiratory Flow (PEF) monitoring for one week
B. Chest X-ray showing hyperinflation
C. Spirometry showing reversible airflow obstruction
D. Measurement of Fractional Exhaled Nitric Oxide (FeNO)
Answer: C
Rationale: Spirometry is the gold standard for diagnosing asthma by demonstrating
airflow obstruction that is reversible after administration of a bronchodilator.
2. According to GINA guidelines, what is the criteria for significant
bronchodilator reversibility in adults?
A. Increase in FEV1 of >10% and >100 mL
B. Increase in FEV1 of >15% and >300 mL
C. Increase in FEV1 of >20% and >400 mL
D. Increase in FEV1 of >12% and >200 mL
Answer: D
Rationale: A significant bronchodilator response is defined as an increase in FEV1 of more
than 12% and more than 200 mL from the baseline.
,3. A patient has asthma symptoms 3 days a week and wakes up 3 times a month
due to asthma. How is this severity classified?
A. Mild Persistent
B. Intermittent
C. Moderate Persistent
D. Severe Persistent
Answer: A
Rationale: Mild persistent asthma is characterized by symptoms occurring more than 2
days per week (but not daily) and nighttime awakenings 3-4 times per month.
4. Under the GINA 2024 Track 1 recommendation, what is the preferred reliever
for all steps?
A. Short-Acting Beta-Agonist (SABA) alone
B. Oral Corticosteroids
C. Low-dose ICS + Salmeterol
D. Low-dose Inhaled Corticosteroid (ICS) + Formoterol
Answer: D
Rationale: GINA Track 1 recommends low-dose ICS-formoterol as the preferred reliever to
reduce the risk of severe exacerbations compared to using a SABA alone.
5. Which medication is known to have a Black Box Warning for serious
neuropsychiatric events, such as agitation and suicidal thoughts?
A. Montelukast
B. Albuterol
C. Fluticasone
D. Theophylline
Answer: A
Rationale: Montelukast (Singulair) carries a FDA Black Box Warning due to the risk of
serious neuropsychiatric events.
, 6. What is the primary mechanism of action of Omalizumab in treating severe
allergic asthma?
A. IL-5 Inhibition
B. IL-4 Receptor Antagonism
C. Binding to circulating IgE
D. Inhibiting Leukotriene synthesis
Answer: C
Rationale: Omalizumab is a monoclonal antibody that binds to circulating IgE, preventing
it from binding to mast cells and basophils.
7. Which of the following is the most appropriate next step for a patient on
medium-dose ICS-LABA whose asthma remains uncontrolled?
A. Add a Long-Acting Muscarinic Antagonist (LAMA)
B. Switch to SABA only
C. Discontinue ICS and start Montelukast
D. Decrease the ICS dose to minimize side effects
Answer: A
Rationale: For patients uncontrolled on Step 4 (medium-dose ICS-LABA), adding a LAMA
(like Tiotropium) is a recommended option.
8. A 28-year-old pregnant woman has well-controlled asthma on Budesonide.
What is the recommendation regarding her treatment?
A. Stop all medications to protect the fetus
B. Switch to a SABA only
C. Switch to oral prednisone
D. Continue the current ICS as the benefits of control outweigh risks
Answer: D
Rationale: Maintaining asthma control is vital during pregnancy; Budesonide is the
preferred ICS due to extensive safety data, and treatment should continue.
